Articles tagged "Induction therapy"

2019 American Transplant Congress
Effect of ATG on Monocytic Myeloid-Derived Suppressor Cells and Its Associated Mechanisms in Kidney Transplantation Recipients
Y. Jiang, X. Zhang
Beijing Chao-yang Hospital, Beijing, China
*Purpose: Myeloid-derived suppressor cells (MDSCs) consist of heterogeneous myeloid progenitors and precursors that was first defined in cancer patients and are characterized by a immunoregulatory…
2019 American Transplant Congress
Induction with Thymoglobulin in DCD Kidneys. Dose Effect and Predictors of Outcome
A. Asderakis, T. Sabah, A. Jones, E. Ablorsu, L. Szabó, R. Chavez
Cardiff Transplant Unit, University Hospital of Wales, Cardiff, United Kingdom
*Purpose: Thymoglobulin (ATG) is used only in few UK centres as induction. We have previously shown good results with ATG for pancreas transplants. The aim…
2019 American Transplant Congress
Low Dose Thymoglobulin Has No Disadvantages to Standard Higher Dose: A Report of the Midwest Pediatric Nephrology Consortium
I. Ashoor¹, R. Beyl², C. Gupta³, A. Jain⁴, S. Kiessling⁵, H. Patel⁶, J. Sherbotie⁷, D. J. Weaver Jr⁸, R. Zahr⁹, V. Dharnidharka¹⁰
¹LSU Health, New Orleans, LA, ²Pennington Biomedical Research Center, Baton Rouge, LA, ³Children's National Medical Center, Washington, DC, ⁴Wayne State University, Detroit, MI, ⁵University of Kentucky, Lexington, KY, ⁶Nationwide Children's Hospital, Colombus, OH, ⁷University of Utah SOM, Salt Lake City, UT, ⁸Levine Children's Hospital, Charlotte, NC, ⁹University of Tennessee, Memphis, TN, ¹⁰Washington University, St. Louis, MO
*Purpose: What is not known is whether a lower Thymoglobulin (ATG) induction dose provides safe and effective immunosuppression compared to a “standard” higher dose in…
2019 American Transplant Congress
To Each Their Own: Center-Level Variation in Tailoring Induction Immunosuppression to Kidney Transplant Recipients
S. Bae, A. Massie, J. Garonzik Wang, M. McAdams DeMarco, J. Coresh, D. Segev
Johns Hopkins University, Baltimore, MD
*Purpose: Ideally, induction immunosuppression should be selected in a personalized manner. However, there is little knowledge of what clinical factors are considered in this process…
2019 American Transplant Congress
Thymoglobulin Versus Alemtuzumab Induction in High Immunologic Risk Kidney Transplants
J. Lockridge¹, J. Pryor¹, D. Norman¹, A. Olyaei²
¹OHSU, Portland, OR, ²Pharmacy, OHSU, Portland, OR
*Purpose: The optimal induction immunosuppressive therapy to prevent kidney transplant rejection remains controversial, specifically among high immunologic risk patients. Our aim was to compare the…
2019 American Transplant Congress
Efficacy and Safety of Alemtuzumab versus Basiliximab Induction in Lung Transplantation
J. Choe, J. Au, A. Diamond, C. Ruggia-Check, S. Sehgal, F. Cordova, N. Shigemura, S. Keshavamurthy, Y. Toyoda
Temple University Hospital, Philadelphia, PA
*Purpose: Minimal literature exists regarding alemtuzumab for induction in lung transplantation but is the preferred agent at Temple University Hospital (TUH). Basiliximab is reserved for…
2019 American Transplant Congress
Association Of Lymphocyte-depleting Antibody And Steroids Induction With The Risk And Outcomes Of Post-transplant Diabetes: Analysis Of Deceased-donor Kidney Transplants
A. Santos¹, J. Gregg², U. L. Akanit³, K. Alquadan¹, H. Bejjanki¹, K. L. Womer¹
¹Div. of Nephrology, Hypertension & Renal Transplantation, University of Florida, Gainesville, FL, ²University of Florida, Gainesville, FL, ³Ubon Ratchathani University, Ubonratchathani, Thailand
*Purpose: We aimed to determine the risk and outcomes of post-transplant diabetes(PTDM) associated with combined lymphocyte-depleting antibody (LDA) [anti-thymocyte globulin (ATG) or alemtuzumab (ALM)] and…
2019 American Transplant Congress
Combined Antithymocyte Globulin (ATG) and Rituximab (RTX) Induction in African American (AA) Kidney Transplant Recipients
S. J. Patel, S. Kuten, C. Pham, R. Knight, M. Hobeika, D. Nguyen, E. Graviss, S. Yi, T. Eagar, A. Gaber
Methodist Hospital, Houston, TX
*Purpose: We have previously shown that despite the use of T cell-depleting antibody induction, AA kidney transplant recipients (KTR) remain at high risk of rejection…
2019 American Transplant Congress
Comparison of Basiliximab and Alemtuzumab for Lung Transplant Induction
S. Mietz¹, D. Roe², E. Lushin¹, E. Anderson¹, C. Hage²
¹Pharmacy, Indiana University Health, Indianapolis, IN, ²Pulmonary Critical Care, Indiana University Health, Indianapolis, IN
*Purpose: Compare alemtuzumab and basiliximab used for lung transplant in terms of rejection, CLAD, and mortality.*Methods: A retrospective review of lung transplants performed between 2010…
2019 American Transplant Congress
Basiliximab versus T-cell Depleting Induction Therapy in Elderly Kidney Transplant Recipients
G. Vranic, H. Shah, B. Thomas, B. Javaid, J. Moore, M. Cooper, A. Gilbert
MedStar Georgetown Transplant Institute, Washington, DC
*Purpose: The ideal induction therapy for elderly kidney transplant recipients is not known. Given concerns about increased risk of infection and malignancy and perceived decreased…